Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 5
2003 14
2004 21
2005 10
2006 18
2007 19
2008 11
2009 16
2010 22
2011 24
2012 21
2013 22
2014 25
2015 29
2016 30
2017 41
2018 39
2019 17
2020 17
2021 14
2022 16
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Results by year

Filters applied: . Clear all
Page 1
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Xu RH, et al. Among authors: sakamoto j. Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16. Lancet Oncol. 2018. PMID: 29555258 Clinical Trial.
A Hercule Poirot of clinical research.
Sakamoto J. Sakamoto J. Gastric Cancer. 2016 Jan;19(1):21-3. doi: 10.1007/s10120-015-0555-3. Gastric Cancer. 2016. PMID: 26482151 No abstract available.
Updated evidence on adjuvant treatments for gastric cancer.
Kanda M, Kodera Y, Sakamoto J. Kanda M, et al. Among authors: sakamoto j. Expert Rev Gastroenterol Hepatol. 2015;9(12):1549-60. doi: 10.1586/17474124.2015.1094373. Epub 2015 Sep 28. Expert Rev Gastroenterol Hepatol. 2015. PMID: 26414453 Review.
Cutting-edge evidence of adjuvant treatments for gastric cancer.
Shimizu D, Kanda M, Kodera Y, Sakamoto J. Shimizu D, et al. Among authors: sakamoto j. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1109-1122. doi: 10.1080/17474124.2018.1530985. Epub 2018 Oct 10. Expert Rev Gastroenterol Hepatol. 2018. PMID: 30274536 Review.
Quality of life in gastric cancer.
Kaptein AA, Morita S, Sakamoto J. Kaptein AA, et al. Among authors: sakamoto j. World J Gastroenterol. 2005 Jun 7;11(21):3189-96. doi: 10.3748/wjg.v11.i21.3189. World J Gastroenterol. 2005. PMID: 15929166 Free PMC article. Review.
Efficacy of oral anticancer agents for colorectal cancer.
Sakamoto J, Oba K, Matsui T, Kobayashi M. Sakamoto J, et al. Dis Colon Rectum. 2006 Oct;49(10 Suppl):S82-91. doi: 10.1007/s10350-006-0601-7. Dis Colon Rectum. 2006. PMID: 17106820 Review. No abstract available.
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.
GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group; Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Tsuburaya A, Van Cutsem E, Buyse M. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, et al. Among authors: sakamoto j. Eur J Cancer. 2013 May;49(7):1565-77. doi: 10.1016/j.ejca.2012.12.016. Epub 2013 Jan 24. Eur J Cancer. 2013. PMID: 23352439 Review.
386 results